Biotech Values

[genisi]

What's more interesting to me is what drugs will be combined with PLX to extend the impressive but still relatively modest duration.

And resistance (in addition to limited duration). GSK is running a combo trial of BRAF + MEK Inhibitors in melanoma to eliminate resistance.

http://clinicaltrials.gov/ct2/show/NCT01072175?term=GSK2118436++GSK1120212&rank=1